Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
McMillan
H
H
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008609:Mental Status Schedule; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates; D000068836:Rivastigmine; D012606:Scotland; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine